{"DataElement":{"publicId":"5935695","version":"1","preferredName":"Neoadjuvant Therapy Cytarabine Dose Administration Status","preferredDefinition":"A response used to determine the quantity of cytarabine administered prior to the primary treatment for the purpose of making the primary treatment for effective.","longName":"5935690v1.0:5935693v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"5935690","version":"1","preferredName":"Neoadjuvant Therapy Cytarabine Dose Administration","preferredDefinition":"The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment for effective._A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"5935691v1.0:5935692v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"5935691","version":"1","preferredName":"Neoadjuvant Therapy Cytarabine","preferredDefinition":"The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment for effective.:A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","longName":"C15665:C408","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A9083-D5D1-722D-E053-F662850AEE60","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5935692","version":"1","preferredName":"Dose Administration","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"C25488:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A9083-D5E2-722D-E053-F662850AEE60","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A2D78-53ED-7DEA-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"GARRIDOJ","dateModified":"2017-10-04","changeDescription":"Created for EA4151, 8/18/17 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5935693","version":"1","preferredName":"Cytarabine Dose Administration Status","preferredDefinition":"A condition or state at a particular time.","longName":"5935693v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No high-dose cytarabine","valueDescription":"No High Dose Cytarabine","ValueMeaning":{"publicId":"5935694","version":"1","preferredName":"No High Dose Cytarabine","longName":"5935694","preferredDefinition":"The non-affirmative response to a question.: An elevated level or position or degree; greater than normal in degree or intensity or amount.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A9083-D619-722D-E053-F662850AEE60","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"570A9083-D634-722D-E053-F662850AEE60","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","deletedIndicator":"No"},{"value":"High-dose cytarabine","valueDescription":"High Dose Cytarabine","ValueMeaning":{"publicId":"2769705","version":"1","preferredName":"High Dose Cytarabine","longName":"2769705","preferredDefinition":"High; greater than normal in degree or intensity or amount.: The amount of medicine taken, or radiation given, at one time.: An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5353004C-779C-0F2B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"570A9083-D640-722D-E053-F662850AEE60","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A9083-D5FE-722D-E053-F662850AEE60","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"GARRIDOJ","dateModified":"2017-10-04","changeDescription":"Created for EA4151, 8/18/17 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"3314497","version":"1","longName":"Treatment","context":"ECOG-ACRIN"}]}],"AlternateNames":[{"name":"TtlDsCytRcvd","type":"COG GDE Short Name","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Induction treatment","type":"Preferred Question Text","description":"Induction treatment","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"570A2D78-540A-7DEA-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2017-08-18","modifiedBy":"RODELAA","dateModified":"2019-10-25","changeDescription":"Created for EA4151, 8/18/17 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}